title: [Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress].
abstract: OBJECTIVE
  To evaluate the efficacy of atorvastatin in preventing contrast agent-induced nephropathy (CIN) in patients undergoing coronary angiography and explore the mechanism.
  
  
  METHODS
  A total of 180 patients undergoing coronary angiography or percutaneous coronary interventions (PCI) were randomized into regular dose and high dose atorvastatin groups (n=90). Serum creatinine (Scr), glomerular filtration rate (GFR), cystatin, peripheral blood levels of myeloperoxidase (MPO), malondialdehyde (MDA), and superoxide dismutase (SOD)  before and after the procedure were compared between the two groups.
  
  
  RESULTS
  The incidence of CIN was significantly lower in high-dose atorvastatin group than in the regular dose group. At 48-72 h after the surgery, serum Scr and cystatin levels were significantly lower and eGFR was significantly higher in the high-dose group. At 24 h after the surgery, MPO and MDA levels were significantly lower, and SOD activity was significantly higher in high-dose group than in the regular dose group.
  
  
  CONCLUSIONS
  High-dose atorvastatin used before angiography is more effective than the regular dose in attenuating contrast agent-induced renal dysfunction, and its mechanism is related with the inhibition of oxidative stress.
authors.affiliation: Department of Cardiovascular Diseases, Southern Medical University, Guangzhou, China. csp@fimmu.com
authors.forename: Shiping
authors.initials: S
authors.lastname: Cao
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.forename: Kai
authors.initials: K
authors.lastname: Cui
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Hou
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D003287:Contrast Media; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin